Search research articles
Contact Us
Filters
Showing results (471-480 of 497) with videos related to
Page
of 50
Sort By:
Circulation
|
April 1, 2020
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial
Deepak L Bhatt, John W Eikelboom, Stuart J Connolly, et al.
Journal of the American College of Cardiology
|
December 10, 2013
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)
Shaun G Goodman, Daniel M Wojdyla, Jonathan P Piccini, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|
June 5, 2019
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial
Robert G Hart, Roland C Veltkamp, Patrick Sheridan, et al.
JAMA Neurology
|
July 7, 2020
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial
Roland Veltkamp, Lesly A Pearce, Eleni Korompoki, et al.
Circulation
|
March 18, 2020
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)
Kevin R Bainey, Robert C Welsh, Stuart J Connolly, et al.
The New England Journal of Medicine
|
March 21, 2017
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Jeffrey I Weitz, Anthonie W A Lensing, Martin H Prins, et al.
Molecules (Basel, Switzerland)
|
November 17, 2007
Lipid-lowering effects of ethyl 2-phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in rodents
Justin M Holub, Kathy O'Toole-Colin, Adam Getzel, et al.
Thrombosis Journal
|
November 10, 2018
Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis
Anthony Chan, Anthonie W A Lensing, Dagmar Kubitza, et al.
Circulation
|
September 13, 2019
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis
John W Eikelboom, Stuart J Connolly, Jacqueline Bosch, et al.
Journal of the American College of Cardiology
|
April 18, 2015
Cardiovascular drug development: is it dead or just hibernating?
Christopher B Fordyce, Matthew T Roe, Tariq Ahmad, et al.
Page
of 50
Search research articles
Search
Showing results (471-480 of 497) with videos related to
Sort By:
Page
of 50
Circulation
|
April 1, 2020
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial
Deepak L Bhatt, John W Eikelboom, Stuart J Connolly, et al.
Journal of the American College of Cardiology
|
December 10, 2013
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)
Shaun G Goodman, Daniel M Wojdyla, Jonathan P Piccini, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|
June 5, 2019
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial
Robert G Hart, Roland C Veltkamp, Patrick Sheridan, et al.
JAMA Neurology
|
July 7, 2020
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial
Roland Veltkamp, Lesly A Pearce, Eleni Korompoki, et al.
Circulation
|
March 18, 2020
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)
Kevin R Bainey, Robert C Welsh, Stuart J Connolly, et al.
The New England Journal of Medicine
|
March 21, 2017
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Jeffrey I Weitz, Anthonie W A Lensing, Martin H Prins, et al.
Molecules (Basel, Switzerland)
|
November 17, 2007
Lipid-lowering effects of ethyl 2-phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in rodents
Justin M Holub, Kathy O'Toole-Colin, Adam Getzel, et al.
Thrombosis Journal
|
November 10, 2018
Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis
Anthony Chan, Anthonie W A Lensing, Dagmar Kubitza, et al.
Circulation
|
September 13, 2019
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis
John W Eikelboom, Stuart J Connolly, Jacqueline Bosch, et al.
Journal of the American College of Cardiology
|
April 18, 2015
Cardiovascular drug development: is it dead or just hibernating?
Christopher B Fordyce, Matthew T Roe, Tariq Ahmad, et al.
Page
of 50